NEW YORK, NY - January 30, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (NASDAQ: CORT).

CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION

If you are a Corcept investor and have suffered losses, or if you have information that could assist in the Corcept investigation, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing jcampisi@kaplanfox.com or by calling (212) 329-8571.

On December 31, 2025, before markets opened, Corcept announced in a press release that the “U.S. Food and Drug Administration (FDA or the Agency) has issued a Complete Response Letter (“CRL”) regarding the New Drug Application (NDA) for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.”  The Company stated in the press release that “the Agency concluded it could not arrive at a favorable benefit-risk assessment for relacorilant without Corcept providing additional evidence of effectiveness.”

As a result of this news, on December 31, 2025, the price of Corcept stock declined from a closing price on December 30, 2025 of $70.20 per share to close at $34.80 per share, a decline of $35.40 per share, or over 50%.

Then, on January 30, 2025, a corrected version of the CRL dated January 28, 2026 was widely disseminated in the media and it states “[d]uring the pre-submission meetings, [the FDA], informed [Corcept] on several occasions of [its] concerns about the adequacy of the clinical development program to assess the effect of relacorilant on hypertension in the intended population including the design of CORT 125134-455, and to expect significant review issues if [Corcept] were to submit [its] application.”

Following this news, the price of Corcept stock declined more than $5.60 per share, over 12%, during intraday trading on January 30, 2025.

WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey.  With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand.  Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients.  For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.

If you have any questions about this investigation, please contact:

CONTACT:
Jeffrey P. Campisi
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York 10022
(212) 329-8571
jcampisi@kaplanfox.com

Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1501
Oakland, California 94612
(415) 772-4704
lking@kaplanfox.com

Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.

https://www.kaplanfox.com/case/corcept-therapeutics-inc/

View the original release on www.newmediawire.com